Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: A phase 2, open-label, single-arm study
- Sarina A. Piha-Paul
- , Matthew H. Taylor
- , Daniel Spitz
- , Lee Schwartzberg
- , J. Thaddeus Beck
- , Todd M. Bauer
- , Funda Meric-Bernstam
- , Das Purkayastha
- , Linda Karpiak
- , Sebastian Szpakowski
- , Fadi Braiteh
Research output: Contribution to journal › Article › peer-review